Monitoring of N,N-dimethylacetamide in children during i.v.-busulfan therapy by liquid chromatography-mass spectrometry

Validation of a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of N,N-dimethylacetamide and N-monomethylacetamide in pediatric plasma

N,Na-dimethylacetamide is an excipient used in intravenous busulfan formulations, a drug used in hematopoietic stem cell transplantation conditioning. The aim of this study was to develop and validate a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of N,N-dimethylacetamide, and its metabolite N-monomethylacetamide in plasma from children receiving busulfan. A 4 μl aliquot of patient plasma was extracted using 196 μl 50% methanol solution and quantified against calibrators prepared in the extraction solvent given negligible matrix effects across three concentrations. ⁹ [H₂ ]-N,N-dimethylacetamide was used as an internal standard. Separation of N,N-dimethylacetamide and N-monomethylacetamide was achieved using a Kinetex EVO C18 stationary phase (100 mm × 2.1 mm × 2.6 μm) running an isocratic mobile phase of 30% methanol containing 0.1% formic acid at a flow of 0.2 ml/min over 3.0 min. The injection volume was 1 μl. Calibration curves for N,N-dimethylacetamide and N-monomethylacetamide were linear up to 1200 and 200 μg/L, respectively, with a lower limit of quantification 1 μg/L for both analytes. Calibrator accuracy and precision were within ± 10% of the test parameters across four concentration levels. Analytes were stable over 14 days at three different storage conditions. This method was successfully applied to measure N,N-dimethylacetamide and N-monomethylacetamide concentrations in a total of 1265 plasma samples from 77 children.

Simultaneously enhanced degradation of N, N-dimethylacetamide and reduced formation of iron sludge by an efficient electrolysis catalyzed ozone process in the presence of dissolved silicate

The generation of sludge is the main issue in iron-based electrochemical techniques. Interestingly, in this study, the effluent was totally limpid and iron sludge did not generate when dissolved silicate (Na₂SiO₃) was used as the electrolyte in an electrolysis catalyzed ozone (ECO-Na₂SiO₃) system. More importantly, the pseudo-first-order rate constants (0.112 min^-1) for DMAC degradation in ECO-Na₂SiO₃ process was much higher than those of ECO systems using other electrolytes. An inhibition film formed on the iron electrode surface was identified to inhibit excess corrosion of iron electrodes and efficiently catalyze decomposition of ozone simultaneously. It was confirmed that hydroxyl radical (^•OH) played a dominant role for the degradation of DMAC, and O₂^•- and H₂O₂ were also contained in ECO-Na₂SiO₃ system. The contributions of contained oxidative reactions in ECO-Na₂SiO₃ system were quantitatively evaluated. Finally, the degradation pathway of DMAC was proposed. This work provides an effective way for protecting electrode from corrosion in electrochemical process.

Reversible Contraceptive Potential of FDA Approved Excipient N, N-Dimethylacetamide in Male Rats

Development of an effective male contraceptive agent remains a challenge. The present study evaluates the potential of N, N-Dimethylacetamide (DMA), a FDA approved excipient as a male contraceptive agent. Male Sprague Dawley rats injected with DMA for a period of 8 weeks (one injection per week) showed a significant alteration of reproductive parameters. Furthermore, DMA treated animals showed complete infertility in a dose dependent manner, as no pups were born despite proper mating between females and DMA treated males. However, stopping the DMA treatment for a period of 8 weeks (after the initial treatment) restored the reproductive parameters to normal. Moreover, the fertility was resumed to normal as pups were born in the groups where DMA treatment was halted after initial DMA treatment. All these changes had no effect on the level of reproductive hormones FSH, LH and testosterone. Taken together, our results indicate that DMA acts in a reversible and non-hormonal manner to achieve contraception in rats. Therefore, repurposing the use of DMA could lead in a short time to an inexpensive and safer male contraceptive option.

N, N-Dimethylacetamide, an FDA approved excipient, acts post-meiotically to impair spermatogenesis and cause infertility in rats

N, N-Dimethylacetamide is an FDA approved solvent widely used in pharmaceutical industry to facilitate the solubility of lipophilic, high molecular weight drugs with poor water solubility. However, the cytotoxic effects of DMA raises the concern about its use in clinical applications. In the present study, we address the effect of DMA on spermatogenesis. Male Sprague Dawley rats were injected intra-peritoneally for 8 weeks, once a week at a dose of 862 mg/kg. Analysis of reproductive parameters revealed that DMA treated animals exhibit spermatid formation defects within the testis describing the characteristics of oligozoospermia. A subsequent decrease in epididymal sperm concentration along with distortion of sperm morphology was observed. The mitochondrial and microtubule organization in the sperm is considerably modified by DMA. This disrupts the sperm kinetics thus decreasing the total and progressive sperm motility. Finally, DMA treatment resulted in loss of fertility. Our results indicate that exposure to DMA has a negative impact on spermatogenesis and leads to infertility in male rats by inhibiting the post meiotic stages of sperm development. Therefore, the use of DMA in humans must be closely monitored.

Development and Characterization of Liquisolid Tablets Based on Mesoporous Clays or Silicas for Improving Glyburide Dissolution

The aim of this work was to evaluate the effectiveness of mesoporous clays or silicas to develop fast-dissolving glyburide tablets based on a liquisolid approach. Selected clay (Neusilin^®US2) and silica (Aeroperl^®300) allowed preparation of innovative drug liquisolid systems containing dimethylacetamide or 2-pyrrolidone as drug solvents, without using coating materials which are necessary in conventional systems. The obtained liquisolid powders were characterized for solid-state properties, flowability, compressibility, morphology, granulometry, and then used for directly compressed tablet preparation. The developed liquisolid tablets provided a marked drug dissolution increase, reaching 98% dissolved drug after 60 min, compared to 40% and 50% obtained from a reference tablet containing the plain drug, and a commercial tablet. The improved glyburide dissolution was attributed to its increased wetting properties and surface area, due to its amorphization/solubilization within the liquisolid matrix, as confirmed by DSC and PXRD studies. Mesoporous clay and silica, owing to their excellent adsorbent, flow, and compressibility properties, avoided use of coating materials and considerably improved liquid-loading capacity, reducing the carrier amount necessary to obtain freely flowing powders. Neusilin^®US2 showed a superior performance than Aeroperl^®300 in terms of the tablet’s technological properties. Finally, simplicity and cost-effectiveness of the proposed approach make it particularly advantageous for industrial scale-up.

The Release of the Bromodomain Ligand N,N-Dimethylacetamide Adds Bioactivity to a Resorbable Guided Bone Regeneration Membrane in a Rabbit Calvarial Defect Model

N,N-Dimethylacetamide (DMA) is FDA approved as an excipient and is used as drug-delivery vehicle. Due to its amphipathic nature and diverse bioactivities, it appears to be a good combination of biodegradable poly-lactide-co-glycolide (PLGA)-based guided bone regeneration membranes. Here we show that the solvent DMA can be loaded to PLGA membranes by different regimes, leading to distinct release profiles, and enhancing the bone regeneration in vivo. Our results highlight the potential therapeutic benefits of DMA in guided bone regeneration procedures, in combination with biodegradable PLGA membranes.

Natural mackinawite catalytic ozonation for N, N-dimethylacetamide (DMAC) degradation in aqueous solution: Kinetic, performance, biotoxicity and mechanism

To enhance the degradation of N, N-dimethylacetamide (DMAC) in aqueous solution, the natural mackinawite (NM) is introduced for catalytic ozonation in this study as it is an environmentally friendly catalyst with low cost and easy availability. The properties of the NM were initially characterized via scanning electron microscopy (SEM), energy dispersive X-ray spectroscopy (EDS), X-ray diffraction (XRD), Fourier Transform infrared spectroscopy (FTIR) and X-ray photoelectron spectroscopy (XPS). Then, impact factors including NM dosage, ozone gas concentration and initial pH were investigated and the optimal conditions (i.e., NM dosage = 3.5 g/L, ozone gas concentration = 300 L/min, initial pH = 6.8) were obtained in NM/O3 process. Besides, the superiority of the NM/O₃ process was confirmed by the experiments that the degradation efficiency of DMAC in the NM/O₃ process (i.e., 95.4%) was much higher than that in the zero-valent iron (ZVI)/O₃ process (i.e., 46.1%) and the synthetic FeS/O₃ process (i.e., 68.6%). Furthermore, the intermediate and possible degradation pathway of DMAC were proposed, and the biological toxicity of the intermediate was subsequently evaluated by the activated sludge. Finally, the mechanism of the NM/O3 process was proposed in this study based on control experiment and radical scavenging experiment. The extraordinary efficiency for DMAC degradation was found to be mainly caused by HO^• of the reactive oxygen species (ROS) (i.e., HO^•, O₂^•- and H₂O₂) generated in the NM/O₃ process. Therefore, this study confirmed that NM was a high efficient catalyst for degradation the toxic and refractory pollutants in catalytic ozonation system.

Insight into a highly efficient electrolysis-ozone process for N,N-dimethylacetamide degradation: Quantitative analysis of the role of catalytic ozonation, fenton-like and peroxone reactions

A highly efficient electrolysis catalyzed ozone (ECO) process was developed for N,N-dimethylacetamide (DMAC) degradation. The pseudo-first-order rate constants (k_obs) of DMAC degradation by ECO process were 1.73-19.09 times greater than those by ozonation and electrolysis processes in a wide pH range of 3.0-10.0. Interestingly, we found O₂^•- could be generated from ozone decomposition by a radical chain mechanism instead of monovalent reduction of O₂ in ECO system at the initial pH of 3.0. Subsequently, the H₂O₂ derived from O₂^•- could participate in Fenton-like and peroxone reactions with the released Fe²⁺ from iron anode and the aerated O₃, respectively. Therefore, the extraordinary DMAC removal efficiency was mainly caused by the more generation of ^•OH through the multiple reactions of homogeneous catalytic ozonation, Fenton-like and peroxone in ECO system. Importantly, the roles of involved reactions in ECO system at various initial pH were quantitatively evaluated according to a series of trapping experiments. The results reveal that the solution pH could significantly affect the contributions of various reactions and convert the reaction mechanisms of multiple reactions in ECO system. Finally, the degradation intermediates were detected to propose a possible DMAC oxidation pathway in the ECO system. This work provides a deep insight into the quantitative analysis of the role of multiple oxidation reactions mechanism and the design of efficient electrochemical advanced oxidation technology for recalcitrant organic pollutant removal.

New insights into the treatment of realN,N-dimethylacetamide contaminated wastewater using a membrane bioreactor and its membrane fouling implications

Treatment of N,N-dimethylacetamide (DMAC) wastewater is an important step in achieving the sustainable industrial application of DMAC as an organic solvent. This is the first time that treatment of a high concentration of DMAC in real wastewater has been assessed using membrane bioreactor technology. In this study, an anoxic–oxic membrane bioreactor (MBR) was operated over a month to mineralize concentrated DMAC wastewater. Severe membrane fouling occurred during the short-term operation of the MBR as the membrane flux decreased from 11.52 to 5.28 L (m² h)⁻¹. The membrane fouling was aggravated by the increased amount of protein fractions present in the MBR mixed liquor. Moreover, results from the excitation–emission matrix analysis identified tryptophan and other protein-like related substances as the major membrane-fouling components. Furthermore, analysis of the DMAC degradation mechanism via high performance liquid chromatography (HPLC) and ion chromatography (IC) revealed that the major degradation products were ammonium and dimethylamine (DMA). Although the MBR system achieved the steady removal of DMAC and chemical oxygen demand (COD) by up to 98% and 80%, respectively at DMAC₀ ≤ 7548 mg L⁻¹, DMA was found to have accumulated in the treated effluent. Our investigation provides insight into the prospect and challenges of using MBR systems for DMAC wastewater degradation.

Treatment of N,N-dimethylacetamide (DMAC) wastewater is an important step in achieving the sustainable industrial application of DMAC as an organic solvent.

Biodegradation of N,N-dimethylacetamide by Rhodococcus sp. strain B83 isolated from the rhizosphere of pagoda tree

The biodegradation characteristic and potential metabolic pathway for removal of environmental N,N-dimethylacetamide (DMAC) by Rhodococcus sp. strain B83 was studied. Rhodococcus sp. strain B83 was isolated from the rhizosphere of a pagoda tree and proved capable of utilizing DMAC as sole source of carbon and nitrogen. Batch culture studies showed that strain B83 could tolerate up to 25g/L DMAC and showed distinct growth on possible catabolic intermediates except for acetate. The nitrogen balance analysis revealed that approximately 71% of the initial nitrogen was converted to organic nitrogen. DMAC degradation has led to accumulation of acetate and organic nitrogen, meanwhile traces of nitrate and ammonia was build-up but without nitrite. The growth of strain B83 could be inhibited by adding exogenous acetate. By means of the assay of enzymatic degradation of DMAC, several catabolic intermediates at different intervals were observed and identified. Based on the results obtained from culture solution and enzymatic degradation assay, a detailed pathway is proposed for DMAC biodegradation.

N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment

N,N-Dimethylacetamide (DMA) is a water-miscible solvent, FDA approved as excipient and therefore widely used as drug-delivery vehicle. As such, DMA should be devoid of any bioactivity. Here we report that DMA is epigenetically active since it binds bromodomains and inhibits osteoclastogenesis and inflammation. Moreover, DMA enhances bone regeneration in vivo. Therefore, our in vivo and in vitro data reveal DMA's potential as an anti-osteoporotic agent via the inhibition of osteoclast mediated bone resorption and enhanced bone regeneration. Our results highlight the potential therapeutic benefits of DMA and the need for reconsideration of previous reports where DMA was used as an 'inactive' drug-delivery vehicle.

Quantification of human plasma-busulfan concentration by liquid chromatography-tandem mass spectrometry

Background

Busulfan, an alkylating agent administered prior to hematopoietic stem cell transplantation, has a narrow therapeutic range and wide variability in metabolism. We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for rapid and accurate quantification of plasma busulfan.

Methods

Busulfan was separated and detected using an LC system containing a C18 column equipped with MS/MS. The sample was eluted with a mobile phase gradient for a total run time of 10 min. Plasma busulfan concentration was quantified against a 6-point standard curve in a multiple reaction monitoring mode at mass-to-charge (m/z) 264.1 > 151.1. Precision, recovery, matrix effect, linearity, detection capability, carryover, and stability were evaluated. The range of plasma busulfan concentration was obtained by analyzing samples from 9 children receiving busulfan.

Results

The coefficients of variation of within-run and within-laboratory precision were all below 5%. Recoveries were all within the range of 100-105%. Linearity was verified from 0 to 5,000 ng/mL. Limit of detection and limit of quantification were 1.56 and 25 ng/mL, respectively. Carryover rate was within allowable limits. Plasma busulfan concentration was stable for 2 weeks at -20℃ and -80℃, but decreased by 25% when the plasma was stored for 24 hr at room temperature, and by <5% in 24 hr at 4℃. The plasma busulfan concentrations were between 347 ng/mL and 5,076 ng/mL.

Conclusions

Our method using LC-MS/MS enables highly accurate, reproducible, and rapid busulfan monitoring with minimal sample preparation. The method may also enable safe and proper dosage.

Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration

PURPOSE

N,N-dimethylacetamide (DMA) is administered to children during high-dose chemotherapy as a solubilizer with the intravenous formulation of busulfan (Busilvex®). DMA has shown liver toxicity in rats. However, little is known regarding its pharmacokinetics (PK) in humans. The aim of this analysis was to compare the PK of DMA after a once-daily dose of Busilvex® with the standard scheme consisting of 3-4 administrations per day in children.

METHODS

Out of 42 children, aged 0.1-18.9 years, receiving Busilvex®, 18 children received the first dose as a loading dose, giving a double dose of 1.4-2.0 mg/kg over a 4 h infusion followed by 15 doses of 0.7-1.0 mg/kg as 2 h infusions every 6 h. The other 24 children received Busilvex® as 3 h infusions once-daily for 4 consecutive days with a targeted busulfan AUC of 4,263 μM*min. Using NONMEM™ plasma, concentration-time data were analyzed. Assuming an increase in clearance overtime as found in our previous investigation, separate time factors for the two different dosing schedules included in the dataset were tested.

RESULTS

A one-compartment model with clearance increasing over time described the DMA kinetics sufficiently. Peak plasma concentrations of DMA, up to 3.09 mmoL/L (median 0.75 mmoL/L) for the current licensed dose regimen and up to 8.77 mmoL/L (median 3 mmoL/L) for the once-daily application, were observed. The examined increase in clearance was found to be 58 mL/h/kg and 6.1 mL/h/kg per day for the current licensed and the once-daily dose regimen, respectively.

CONCLUSION

N,N-dimethylacetamide as solvent of lipophilic drugs such as busulfan has a linear PK in children of all ages using a dose split into one or four administrations per day. The rapid clearance with different dosing in patients of different body weights indicates that it is safe to use DMA in children in both a once and four times daily regimen.

Cytotoxicity of Dimethylacetamide and Pharmacokinetics in Children Receiving Intravenous Busulfan

Purpose

To assess the cytotoxicity and the exposure of N,N-dimethylacetamide (DMA) in children during high-dose therapy with an intravenous (IV) formulation of busulfan containing the potentially hepatotoxic and neurotoxic DMA as a solvent.

Patients and Methods

Eighteen children aged 0.9 to 17.3 years (median age, 4.0 years) received IV busulfan in 15 doses of 0.7 to 1.0 mg/kg busulfan containing overall DMA amounts of between 5 mmol (437 mg) and 70.5 mmol (6,142 mg) per dose. Plasma concentrations of DMA and busulfan were quantified and analyzed using nonlinear mixed-effects modeling. Four different leukemic cell lines were incubated with DMA, and cytotoxicity was assessed in comparison with busulfan as well as in a combination reflecting the ratio in the formulation.

Results

Maximal plasma concentrations of DMA up to 3.09 mmol/L were observed. No accumulation of the solvent occurred. Instead, the trough levels decreased over the 4 treatment days. The population pharmacokinetic analysis revealed a clearance of 86.9 mL h−1kg−1± 27% that increased to 298 mL h−1kg−1on the fourth day and a volume of distribution of 469 mL kg ± 22% (population mean ± interindividual variability). DMA volume of distribution correlated with the volume of distribution of busulfan. The cytotoxicity of DMA in vitro was 3 orders of magnitude lower than that of busulfan. No synergism was observed.

Conclusion

The lack of accumulation of DMA confirms that there is no safety concern related to the DMA content in this IV busulfan formulation. The contribution of DMA to the antileukemic effect of the formulation seems to be limited.